Will Pickering
Analyst
Bernstein
Equibles does not estimate personal net worth.
About Will Pickering
Will Pickering is recorded as Analyst at Bernstein. Will Pickering has spoken on 2 earnings calls and 2 other investor events across 3 companies, most recently for Roivant Sciences Ltd. on May 29, 2026. Those appearances were for Vertex Pharmaceuticals Inc (VRTX), Roivant Sciences Ltd. (ROIV) and Beam Therapeutics Inc. (BEAM). The companies whose calls Will Pickering spoke on are classified in the Healthcare sector.
Will Pickering on recent calls
“I have the privilege of sharing the stage with Matt Klein, CEO of Roivant. The company has had a remarkable run over the past year, certainly with Brepo as the standout but far from the only value driver.”
“I'm privileged to be sharing the stage with Dr. Reshma Keoramani, CEO of Vertex. The company looks very different today from just a few years ago, building on the base in CF with launches in pain, sickle cell, and soon to be in IGAN.”
“First is, could you explain why a lower editing rate seems to be needed here compared to, say, sickle or AATD and any risk to that translating to humans?”
“I was wondering, this is a POVI one, if you could discuss how you expect the baseline GFR to impact the observed effect size. I think your phase two patients had an average GFR about 10 mils higher than the competitor phase two or phase three trials.”
Affiliation history
-
Bernstein
Analyst
Transcript header (unverified)
Current